JP2018536393A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018536393A5 JP2018536393A5 JP2018518451A JP2018518451A JP2018536393A5 JP 2018536393 A5 JP2018536393 A5 JP 2018536393A5 JP 2018518451 A JP2018518451 A JP 2018518451A JP 2018518451 A JP2018518451 A JP 2018518451A JP 2018536393 A5 JP2018536393 A5 JP 2018536393A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- region
- antibody
- fragment
- hla
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000004965 antibodies Human genes 0.000 claims 22
- 108090001123 antibodies Proteins 0.000 claims 22
- 108010088729 HLA-A*02:01 antigen Proteins 0.000 claims 9
- 210000004027 cells Anatomy 0.000 claims 6
- 150000007523 nucleic acids Chemical class 0.000 claims 6
- 229920001850 Nucleic acid sequence Polymers 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 238000002965 ELISA Methods 0.000 claims 1
- 230000035693 Fab Effects 0.000 claims 1
- 102000018358 Immunoglobulins Human genes 0.000 claims 1
- 108060003951 Immunoglobulins Proteins 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562239438P | 2015-10-09 | 2015-10-09 | |
US62/239,438 | 2015-10-09 | ||
GBGB1517913.8A GB201517913D0 (en) | 2015-10-09 | 2015-10-09 | Anti-WT1/HLA-specific antibodies |
GB1517913.8 | 2015-10-09 | ||
EP15189753.5 | 2015-10-14 | ||
EP15189753 | 2015-10-14 | ||
PCT/EP2016/073587 WO2017060201A1 (en) | 2015-10-09 | 2016-10-04 | Anti-wt1/hla-specific antibodies |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2018536393A JP2018536393A (ja) | 2018-12-13 |
JP2018536393A5 true JP2018536393A5 (US20080131398A1-20080605-C00009.png) | 2019-11-14 |
JP6862435B2 JP6862435B2 (ja) | 2021-04-21 |
Family
ID=58487775
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018518451A Active JP6862435B2 (ja) | 2015-10-09 | 2016-10-04 | 抗wt1/hla特異的抗体 |
Country Status (6)
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ754222A (en) | 2016-12-08 | 2022-02-25 | Immatics Biotechnologies Gmbh | T cell receptors with improved pairing |
DE102016123893A1 (de) | 2016-12-08 | 2018-06-14 | Immatics Biotechnologies Gmbh | T-Zellrezeptoren mit verbesserter Bindung |
US11419895B2 (en) | 2017-05-31 | 2022-08-23 | Crage Medical Co., Limited | Compositions and methods of cellular immunotherapy |
DK3428194T3 (da) | 2017-07-14 | 2021-11-15 | Immatics Biotechnologies Gmbh | Forbedret polypeptidmolekyle med dobbelt specificitet |
DE102017127984B4 (de) | 2017-11-27 | 2019-12-05 | Immatics US, Inc. | Verfahren für die Vermehrung und Aktivierung von γδ-T-Zellen |
AR114001A1 (es) | 2017-12-21 | 2020-07-08 | Hoffmann La Roche | Anticuerpos que se unen a hla- a2 / wt1 |
AU2019218093A1 (en) | 2018-02-09 | 2020-09-10 | Immatics US, Inc. | Methods for manufacturing T cells |
WO2020191172A1 (en) | 2019-03-19 | 2020-09-24 | Immatics US, Inc. | Cd28 t cell cultures, compositions, and methods of using thereof |
AU2020283500A1 (en) | 2019-05-27 | 2022-01-27 | Immatics US, Inc. | Viral vectors and their use in adoptive cellular therapy |
SG11202112561UA (en) | 2019-06-06 | 2021-12-30 | Immatics Biotechnologies Gmbh | Sorting with counter selection using sequence similar peptides |
US20210032370A1 (en) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Recruiting agent further binding an mhc molecule |
AU2021225817A1 (en) | 2020-02-24 | 2022-10-20 | Immatics US, Inc. | Methods for expanding T cells for the treatment of cancer and related malignancies |
DE102020106710A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
DE102020111571A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
WO2022040631A1 (en) | 2020-08-21 | 2022-02-24 | Immatics US, Inc. | Methods for isolating cd8+ selected t cells |
JP2024502034A (ja) | 2020-12-31 | 2024-01-17 | イマティクス ユーエス,アイエヌシー. | Cd8ポリペプチド、組成物、及びそれらの使用方法 |
CA3217739A1 (en) | 2021-05-05 | 2022-11-10 | Sebastian Bunk | Bma031 antigen binding polypeptides |
WO2023025851A1 (en) | 2021-08-24 | 2023-03-02 | Immatics US, Inc. | Selection of immune cells using peptide mhc complexes generated by conditional ligand exchange |
US20230089392A1 (en) | 2021-09-20 | 2023-03-23 | Immatics US, Inc. | Monocyte depletion of t cells populations for t-cell therapy |
US20230192886A1 (en) | 2021-11-08 | 2023-06-22 | Immatics Biotechnologies Gmbh | Adoptive cell therapy combination treatment and compositions thereof |
WO2023212697A1 (en) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof |
WO2023212691A1 (en) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | DOMINANT NEGATIVE TGFβ RECEPTOR POLYPEPTIDES, CD8 POLYPEPTIDES, CELLS, COMPOSITIONS, AND METHODS OF USING THEREOF |
WO2023212655A1 (en) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof |
US20230355678A1 (en) | 2022-05-05 | 2023-11-09 | Immatics US, Inc. | Methods for improving t cell efficacy |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012135854A2 (en) * | 2011-04-01 | 2012-10-04 | Memorial Sloan-Kettering Cancer Center | Antibodies to cytosolic peptides |
US20140271644A1 (en) * | 2013-03-15 | 2014-09-18 | Memorial Sloan-Kettering Cancer Center | Combination/adjuvant therapy for wt-1-positive disease |
AU2014346648A1 (en) * | 2013-11-07 | 2016-06-23 | Eureka Therapeutics, Inc. | Fc-enhanced anti-WT1/HLA antibody |
EP3066130B1 (en) * | 2013-11-07 | 2019-05-15 | Memorial Sloan-Kettering Cancer Center | Anti-wt1/hla bi-specific antibody |
US20160152725A1 (en) * | 2014-02-25 | 2016-06-02 | Memorial Sloan-Kettering Cancer Center | Antigen-binding proteins specific for hla-a2-restricted wilms tumor 1 peptide |
-
2016
- 2016-10-04 WO PCT/EP2016/073587 patent/WO2017060201A1/en active Application Filing
- 2016-10-04 MA MA045004A patent/MA45004A/fr unknown
- 2016-10-04 JP JP2018518451A patent/JP6862435B2/ja active Active
- 2016-10-04 EP EP16782018.2A patent/EP3359565A1/en not_active Ceased
- 2016-10-07 US US15/288,145 patent/US10836829B2/en active Active
-
2019
- 2019-01-16 HK HK19100718.0A patent/HK1258444A1/zh unknown
-
2020
- 2020-10-13 US US17/069,136 patent/US20210024635A1/en active Pending